检测 iPSC 衍生视网膜色素上皮细胞分化后的残余 iPSC。

IF 1.9 4区 医学 Q2 OPHTHALMOLOGY
Matthew Hill, Cynthia Andrews-Pfannkoch, Evan Atherton, Travis Knudsen, Emma Trncic, Alan D Marmorstein
{"title":"检测 iPSC 衍生视网膜色素上皮细胞分化后的残余 iPSC。","authors":"Matthew Hill, Cynthia Andrews-Pfannkoch, Evan Atherton, Travis Knudsen, Emma Trncic, Alan D Marmorstein","doi":"10.1089/jop.2024.0130","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Purpose:</i></b> The goal of this study was to develop a lot release assay for iPSC residuals following directed differentiation of iPSCs to retinal pigment epithelial (RPE) cells. <b><i>Methods:</i></b> RNA Sequencing (RNA Seq) of iPSCs and RPE derived from them was used to identify pluripotency markers downregulated in RPE cells. Quantitative real time PCR (qPCR) was then applied to assess iPSC residuals in iPSC-derived RPE. The limit of detection (LOD) of the assay was determined by performing spike-in assays with known quantities of iPSCs serially diluted into an RPE suspension. <b><i>Results:</i></b> <i>ZSCAN10</i> and <i>LIN28A</i> were among 8 pluripotency markers identified by RNA Seq as downregulated in RPE. Based on copy number and expression of pseudogenes and lncRNAs <i>ZSCAN10</i> and <i>LIN28A</i> were chosen for use in qPCR assays for residual iPSCs. Reverse transcription PCR indicated generally uniform expression of <i>ZSCAN10</i> and <i>LIN28A</i> in 21 clones derived from 8 iPSC donors with no expression of either in RPE cells derived from 5 donor lines. Based on qPCR, <i>ZSCAN10</i>, and <i>LIN28A</i> expression in iPSCs was generally uniform. The LOD for <i>ZSCAN10</i> and <i>LIN28A</i> in qPCR assays was determined using spike in assays of RPE derived from 2 iPSC lines. Analysis of ΔΔC<sub>t</sub> found the limit of detection to be <0.01% of cells, equivalent to <1 iPSC/10,000 RPE cells in both iPSC lines. <b><i>Conclusions:</i></b> qPCR for <i>ZSCAN10</i> and <i>LIN28A</i> detects <1 in 10,000 residual iPSCs in a population of iPSC-derived RPE providing an adequate LOD of iPSC residuals for lot release testing.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Detection of Residual iPSCs Following Differentiation of iPSC-Derived Retinal Pigment Epithelial Cells.\",\"authors\":\"Matthew Hill, Cynthia Andrews-Pfannkoch, Evan Atherton, Travis Knudsen, Emma Trncic, Alan D Marmorstein\",\"doi\":\"10.1089/jop.2024.0130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Purpose:</i></b> The goal of this study was to develop a lot release assay for iPSC residuals following directed differentiation of iPSCs to retinal pigment epithelial (RPE) cells. <b><i>Methods:</i></b> RNA Sequencing (RNA Seq) of iPSCs and RPE derived from them was used to identify pluripotency markers downregulated in RPE cells. Quantitative real time PCR (qPCR) was then applied to assess iPSC residuals in iPSC-derived RPE. The limit of detection (LOD) of the assay was determined by performing spike-in assays with known quantities of iPSCs serially diluted into an RPE suspension. <b><i>Results:</i></b> <i>ZSCAN10</i> and <i>LIN28A</i> were among 8 pluripotency markers identified by RNA Seq as downregulated in RPE. Based on copy number and expression of pseudogenes and lncRNAs <i>ZSCAN10</i> and <i>LIN28A</i> were chosen for use in qPCR assays for residual iPSCs. Reverse transcription PCR indicated generally uniform expression of <i>ZSCAN10</i> and <i>LIN28A</i> in 21 clones derived from 8 iPSC donors with no expression of either in RPE cells derived from 5 donor lines. Based on qPCR, <i>ZSCAN10</i>, and <i>LIN28A</i> expression in iPSCs was generally uniform. The LOD for <i>ZSCAN10</i> and <i>LIN28A</i> in qPCR assays was determined using spike in assays of RPE derived from 2 iPSC lines. Analysis of ΔΔC<sub>t</sub> found the limit of detection to be <0.01% of cells, equivalent to <1 iPSC/10,000 RPE cells in both iPSC lines. <b><i>Conclusions:</i></b> qPCR for <i>ZSCAN10</i> and <i>LIN28A</i> detects <1 in 10,000 residual iPSCs in a population of iPSC-derived RPE providing an adequate LOD of iPSC residuals for lot release testing.</p>\",\"PeriodicalId\":16689,\"journal\":{\"name\":\"Journal of Ocular Pharmacology and Therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ocular Pharmacology and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/jop.2024.0130\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ocular Pharmacology and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jop.2024.0130","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在开发一种批量释放检测方法,用于检测 iPSCs 定向分化为视网膜色素上皮细胞(RPE)后的 iPSCs 残留。方法:RNA 测序(RNA Sequencing):对 iPSCs 及其衍生的 RPE 进行 RNA 测序(RNA Seq),以确定 RPE 细胞中下调的多能性标记。然后应用定量实时 PCR (qPCR) 技术评估 iPSC 衍生的 RPE 中的 iPSC 残留。该检测方法的检测限 (LOD) 是通过将已知数量的 iPSCs 按一定比例稀释到 RPE 悬浮液中进行加标检测来确定的。结果通过 RNA Seq 鉴定,ZSCAN10 和 LIN28A 是在 RPE 中下调的 8 个多能性标记物之一。根据假基因和 lncRNA 的拷贝数和表达情况,ZSCAN10 和 LIN28A 被选中用于残留 iPSCs 的 qPCR 检测。反转录 PCR 显示,在来自 8 个 iPSC 供体的 21 个克隆中,ZSCAN10 和 LIN28A 的表达基本一致,而在来自 5 个供体系的 RPE 细胞中,两者均无表达。根据 qPCR,iPSCs 中 ZSCAN10 和 LIN28A 的表达基本一致。qPCR 检测中 ZSCAN10 和 LIN28A 的 LOD 是通过对 2 个 iPSC 品系的 RPE 进行尖峰检测确定的。对 ΔΔCt 的分析发现检测限为 结论:qPCR 检测 ZSCAN10 和 LIN28A 能检测出
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Detection of Residual iPSCs Following Differentiation of iPSC-Derived Retinal Pigment Epithelial Cells.

Purpose: The goal of this study was to develop a lot release assay for iPSC residuals following directed differentiation of iPSCs to retinal pigment epithelial (RPE) cells. Methods: RNA Sequencing (RNA Seq) of iPSCs and RPE derived from them was used to identify pluripotency markers downregulated in RPE cells. Quantitative real time PCR (qPCR) was then applied to assess iPSC residuals in iPSC-derived RPE. The limit of detection (LOD) of the assay was determined by performing spike-in assays with known quantities of iPSCs serially diluted into an RPE suspension. Results: ZSCAN10 and LIN28A were among 8 pluripotency markers identified by RNA Seq as downregulated in RPE. Based on copy number and expression of pseudogenes and lncRNAs ZSCAN10 and LIN28A were chosen for use in qPCR assays for residual iPSCs. Reverse transcription PCR indicated generally uniform expression of ZSCAN10 and LIN28A in 21 clones derived from 8 iPSC donors with no expression of either in RPE cells derived from 5 donor lines. Based on qPCR, ZSCAN10, and LIN28A expression in iPSCs was generally uniform. The LOD for ZSCAN10 and LIN28A in qPCR assays was determined using spike in assays of RPE derived from 2 iPSC lines. Analysis of ΔΔCt found the limit of detection to be <0.01% of cells, equivalent to <1 iPSC/10,000 RPE cells in both iPSC lines. Conclusions: qPCR for ZSCAN10 and LIN28A detects <1 in 10,000 residual iPSCs in a population of iPSC-derived RPE providing an adequate LOD of iPSC residuals for lot release testing.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.60
自引率
4.30%
发文量
72
审稿时长
1 months
期刊介绍: Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信